Condition
Healthy Female
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 4 (1)
Trial Status
Completed2
Recruiting1
Not Yet Recruiting1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03296098Phase 2Withdrawn
Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive
NCT05706753Phase 1CompletedPrimary
A Study of Milvexian in Healthy Adult Females
NCT06886594Not ApplicableCompleted
The Effect of BSE Training on Breast Cancer Knowledge Level and Health Beliefs
NCT05875571Phase 4Recruiting
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
NCT06346457Not Yet Recruiting
Breast Cancer & Antiestrogenic Therapy & Brain
Showing all 5 trials